METHOD FOR ASSESSING THE RESIDUAL MODIFIABLE RISK OF CARDIOVASCULAR COMPLICATIONS DURING PHARMACOTHERAPY IN PATIENTS WITH STABLE EXERTIONAL ANGINA Russian patent published in 2023 - IPC A61B5/02 G01N33/66 G01N33/92 

FIELD: medicine; cardiology.

SUBSTANCE: invention can be used to predict the residual modifiable risk of cardiovascular complications (CVE). In patients with coronary artery disease, stable angina pectoris, by questioning and analyzing the patient's medical records, information about the anamnesis, data on the presence of concomitant diseases affecting the cardiovascular system, and modifiable risk factors for cardiovascular events are collected and analyzed, if necessary, an additional diagnostic examination is performed, in particular: ECG, Holter ECG monitoring, echocardiography, assess the level of blood pressure during self-control of blood pressure or daily monitoring of blood pressure, indicators of glycated hemoglobin (HbAlC), low-density lipoprotein cholesterol (LDL cholesterol). The presence of concomitant diseases related to absolute contraindications to taking the recommended for IHD drug therapy with beta-blockers (BB) is determined. Evaluate on the basis of the patient's history, analysis of his medical records and a survey of the necessary and prescribed drug therapy. Using the NODF Adherence Scale, the patient's adherence to each type of therapy is determined. Upon reaching the target levels of blood pressure, LDL cholesterol, HbAlC, the effectiveness of therapy is evaluated. Then the index of rational pharmacotherapy (IRFT) is calculated according to the formula. Next, the residual modifiable risk of CVC during pharmacotherapy in patients with stable exertional angina is assessed by the value of the index of rational pharmacotherapy (IRPT), where, with a result of 0–25%, it is defined as a very high risk, with a result of 26–50% as a high risk, with 51–75 % as medium risk, and with a value of 76–100% as low risk.

EFFECT: method allows to carry out an objective, universal and accurate personalized assessment of the residual risk in case of drug correction of modifiable risk factors for cardiovascular events in patients with coronary artery disease, stable angina pectoris by assessing the totality of the most significant indicators.

1 cl, 2 tbl, 4 ex